Position of the Transparency Council – Rezurock (belumosudil)

At its meeting on 18 July 2022 the Transparency Council adopted Position No. 67/2022 on the legitimacy of granting reimbursement approval for the medicinal product Rezurock (belumosudil) for the indication: treatment of adult and paediatric patients aged 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two previous lines of systemic treatment.

Publication in Public Information Bulletin (BIP)